PHASE I CLINICAL TRIALS FOR PSORIASIS TX

Article

Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.

Related Videos
Related Content

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.